SCHEMBL23405487

SCHEMBL23405487

Nc1c(-c2ccc(O)c(O)c2)nnn1-c1ccc(Cl)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
POLB P06746 2/20 0.49
ALOX5 P09917 1/20 0.47
PRKCZ Q05513 2/20 0.45
MAPT P10636 2/20 0.43
HTT P42858 2/20 0.40
SNCA P37840 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
CA4 P22748 4/20 0.40
CA9 Q16790 4/20 0.40
PTGS2 P35354 1/20 0.39
LMNA P02545 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405504 0.92 TP53 (0.63) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL27820980 0.78 NPC1 (0.88) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL23405480 0.77 NPC1 (0.55) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL27821065 0.76 NPC1 (0.69) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL23405497 0.72 POLB (0.62) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL548302 0.69 POLB (0.69) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL23405496 0.69 MAPT (0.78) RAB9AALOX5MAPTSNCACA1
SCHEMBL29563142 0.67 ALOX5 (1.00) ALOX5SNCA
SCHEMBL549145 0.67 ALDH1A1 (0.43) TP53MEN1KMT2ANPC1RAB9A
SCHEMBL28461564 0.67 MAPT (0.56) TP53MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 US claimed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 US claimed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US claimed
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 US disclosed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 TP53 3433/4885MEN1 3836/4885KMT2A 2106/4885
US-12297178-B2 Triazole derivative and use thereof FABP4, LIPC, GPR119 TP53 3565/4885MEN1 3803/4885KMT2A 2078/4885
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 TP53 3565/4885MEN1 3803/4885KMT2A 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.